Patents by Inventor Barbara Bertani

Barbara Bertani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240190891
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: June 13, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Claudio FIORELLI, Barbara BERTANI
  • Publication number: 20240116948
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
  • Publication number: 20240018122
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 18, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
  • Patent number: 11780827
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: October 10, 2023
    Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • Publication number: 20230286993
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of formula (I) wherein R1, R2, R3, R5, R6 and A are as defined herein. The compounds of formula (1) are inhibitors of phosphodiesterase 2 and useful in treating central nervous system diseases and other diseases. The invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 11691977
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Patent number: 11660293
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 30, 2023
    Assignee: CHRONOS THERAPEUTICS LIMITED
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Publication number: 20230115176
    Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 13, 2023
    Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
  • Publication number: 20220356172
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 10, 2022
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • Publication number: 20220331299
    Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
    Type: Application
    Filed: August 31, 2018
    Publication date: October 20, 2022
    Inventors: Fabrizio Micheli, Barbara Bertani, Karl Richard Gibson, Romano Di Fabio, Luca Raveglia, Riccardo Zanaletti, Susanna Cremonesi, Alfonso Pozzan, Teresa Semeraro, Luca Tarsi, Timothy Jon Luker
  • Publication number: 20210032259
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 10875867
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Publication number: 20200039991
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 10479794
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: November 19, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Patent number: 10023575
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: July 17, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Publication number: 20180134720
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 17, 2018
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Publication number: 20170101411
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 13, 2017
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 9085584
    Abstract: The compounds are of the class of pyrido[3,2-e][1,2,4]-tiazolo[4,3-a]pyrazines, useful in the treatment of central nervous system disorders.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: July 21, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Barbara Bertani, Sara Frattini, Giustino Di Antonio, Hans-Joachim Lankau, Hans Stange, Christian Grunwald, Norbert Höfgen, Barbara Langen, Ute Egerland
  • Patent number: 9012489
    Abstract: Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 21, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Barbara Bertani, Marco Ferrara, Iain Lingard, Rocco Mazzaferro, Holger Rosenbrock
  • Publication number: 20140045857
    Abstract: The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: July 26, 2013
    Publication date: February 13, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Riccardo GIOVANNINI, Barbara BERTANI, Sara FRATTINI, Giustino DI ANTONIO